Sugi Predict

Sugi Predict / Compounds / SCHEMBL22119280

SCHEMBL22119280

SCHEMBL22119280

Nc1ccnc(N2CCC(F)(F)CC2)c1

nearest known ligand 0.54

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ OPRD1 P41143 16/20 0.54
▸ GRIN2D O15399 1/20 0.50
▸ GRIN3B O60391 1/20 0.50
▸ CHRM1 P11229 1/20 0.50
▸ ADRA1D P25100 1/20 0.50
▸ ADRA1A P35348 1/20 0.50
▸ ADRA1B P35368 1/20 0.50
▸ GRIN1 Q05586 1/20 0.50
▸ GRIN2A Q12879 1/20 0.50
▸ GRIN2B Q13224 1/20 0.50
▸ GRIN2C Q14957 1/20 0.50
▸ GRIN3A Q8TCU5 1/20 0.50
▸ KCNH2 Q12809 10/20 0.49
▸ HRH3 Q9Y5N1 1/20 0.40
▸ KIF18A Q8NI77 1/20 0.39
▸ ADRB1 P08588 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30619312 1.00 OPRD1 (0.54) OPRD1GRIN2DGRIN3BCHRM1ADRA1D
SCHEMBL22148181 0.87 OPRD1 (0.55) OPRD1GRIN2DGRIN3BCHRM1ADRA1D
SCHEMBL28405978 0.82 OPRD1 (0.60) OPRD1GRIN2DGRIN3BCHRM1ADRA1D
SCHEMBL465754 0.80 GRIN2D (0.57) OPRD1GRIN2DGRIN3BCHRM1ADRA1D
SCHEMBL1811254 0.80 GRIN2D (0.57) OPRD1GRIN2DGRIN3BCHRM1ADRA1D
SCHEMBL31346241 0.80 ADRB1 (0.39) OPRD1KIF18AADRB1
SCHEMBL21812367 0.80 ADRB1 (0.39) OPRD1KIF18AADRB1
SCHEMBL29609326 0.80 GRIN2D (0.50) OPRD1GRIN2DGRIN3BGRIN1GRIN2A
SCHEMBL30988524 0.79 GRIN2D (0.55) OPRD1GRIN2DGRIN3BCHRM1ADRA1D
SCHEMBL17095658 0.79 GRIN2D (0.55) OPRD1GRIN2DGRIN3BCHRM1ADRA1D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260098029-A1 KIF18A INHIBITORS AMGEN INC. (US) 2026-04-09 — — US disclosed
US-20260070887-A1 AMIDE OR UREA COMPOUND SHENZHEN ZHONGGE BIOLOGICAL TECH CO LTD (CN) 2026-03-12 — — US disclosed
US-20260062430-A1 INHIBITORS OF KIF18A AND USES THEREOF ACCENT THERAPEUTICS INC (US) 2026-03-05 — — US disclosed
US-12509442-B2 KIF18A inhibitors AMGEN INC. (US) 2025-12-30 — — US disclosed
EP-4628486-A1 AMIDE OR UREA COMPOUND Shenzhen Zhongge Biological Technology Co., Ltd. (CN) 2025-10-08 — — EP disclosed
US-12391709-B2 Inhibitors of KIF18A and uses thereof ACCENT THERAPEUTICS, INC. (US) 2025-08-19 — — US disclosed
EP-4572855-A1 INHIBITORS OF KIF18A AND USES THEREOF Accent Therapeutics, Inc. (US) 2025-06-25 — — EP disclosed
US-20250197428-A1 INHIBITORS OF KIF18A AND USES THEREOF ACCENT THERAPEUTICS, INC. 2025-06-19 — — US disclosed
WO-2024114787-A9 AMIDE OR UREA COMPOUND 深圳众格生物科技有限公司 2025-05-30 — — WO disclosed
US-20240317715-A1 KIF18A INHIBITORS AMGEN INC. (US) 2024-09-26 — — US disclosed
US-11236069-B2 KIF18A inhibitors AMGEN INC. (US) 2022-02-01 — — US disclosed
US-11236069-B2 KIF18A inhibitors AMGEN INC. (US) 2022-02-01 — — US disclosed
WO-2022015957-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY IFM DUE, INC. (US) 2022-01-20 — — WO disclosed
EP-3897852-A1 KIF18A INHIBITORS Amgen Inc. (US) 2021-10-27 — — EP disclosed
CN-113226473-A KIF18A inhibitors 美国安进公司 2021-08-06 — — CN disclosed
US-20200239441-A1 KIF18A INHIBITORS AMGEN INC. (US) 2020-07-30 — — US disclosed
US-20200239441-A1 KIF18A INHIBITORS AMGEN INC. (US) 2020-07-30 — — US disclosed
WO-2020132648-A1 KIF18A INHIBITORS AMGEN INC. (US) 2020-06-25 — — WO disclosed
WO-2020132648-A1 KIF18A INHIBITORS AMGEN INC. (US) 2020-06-25 — — WO disclosed
CN-111196804-A TGF- β R1 inhibitor and application thereof 南京圣和药业股份有限公司 2020-05-26 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12509442-B2 KIF18A inhibitors KIF18A, KIF18B, KIFC1 OPRD1 2939/4885GRIN2D 3549/4885GRIN3B 2882/4885
US-20240317715-A1 KIF18A INHIBITORS KIF18A, KIF18B, KIF15 OPRD1 4586/4885GRIN2D 4134/4885GRIN3B 3652/4885
US-20250197428-A1 INHIBITORS OF KIF18A AND USES THEREOF KIF18A, KIF18B, KIF2C OPRD1 4700/4885GRIN2D 4127/4885GRIN3B 2541/4885
US-20200239441-A1 KIF18A INHIBITORS KIF18A, KIF18B, KIF15 OPRD1 4586/4885GRIN2D 4134/4885GRIN3B 3652/4885
US-12391709-B2 Inhibitors of KIF18A and uses thereof KIF18A, KIF18B, KIF2C OPRD1 4700/4885GRIN2D 4127/4885GRIN3B 2541/4885
US-20260070887-A1 AMIDE OR UREA COMPOUND KIF18A, KIF18B, KIF23 OPRD1 1697/4885GRIN2D 3507/4885GRIN3B 2971/4885
US-20260098029-A1 KIF18A INHIBITORS KIF18A, KIF18B, KIFC1 OPRD1 2875/4885GRIN2D 3512/4885GRIN3B 2819/4885
US-11236069-B2 KIF18A inhibitors KIF18A, KIF18B, KIF15 OPRD1 4586/4885GRIN2D 4134/4885GRIN3B 3652/4885
US-20260062430-A1 INHIBITORS OF KIF18A AND USES THEREOF KIF18A, KIF18B, KIF5B OPRD1 2253/4885GRIN2D 2961/4885GRIN3B 1233/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.